Text Size
Santen Global

2011 IR News

RSS

IR News

Santen New Drug Application Filing Accepted for Review in South Korea and Vietnam for the Use of STN1013001 (Cationic Emulsion of Latanoprost 50μg/mL) in Glaucoma
Santen Announces Status of Share Buyback
【Updated】Corporate Governance Report
Santen and Arctic Vision execute a commercial collaboration agreement for ARVN001, a suprachoroidal space injection therapy for the treatment of uveitic macular edema
Santen Announces Share Buyback
Santen Announces Cancellation of Treasury Shares
Santen Announces Completion of Share Buyback
Santen Reports the 2nd Quarter Fiscal 2024 Consolidated Performance
Santen launches Rhopressa® ophthalmic solution 0.02% (netarsudil mesylate), in South Korea, for the treatment of patients with open-angle glaucoma or ocular hypertension
Santen Announces Status of Share Buyback
Santen Announces Corporate Volunteer Partnership with Be My Eyes
Santen Announces Status of Share Buyback
Notice on the Completion of Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan
Santen applies for manufacturing and marketing approval in Japan for STN1012600 ophthalmic solution (sepetaprost ophthalmic solution), a treatment for glaucoma and ocular hypertension with a novel mechanism of action for lowering intraocular pressure
Santen Publishes its Annual Integrated Report “Santen Report 2024”
Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan
Santen Announces Status of Share Buyback
Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium
Santen Reports the 1st Quarter Fiscal 2024 Consolidated Performance
Santen Announces Status of Share Buyback
Corporate Governance Report
Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Corporate Governance Report
Santen Announces Status of Share Buyback
Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Notice of Corporate Officer Change
Santen Announces Status of Share Buyback
Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis, goes on sale in Japan
Notice of Board of Director and Corporate Auditor Nominations
Notice of Recording of Impairment Loss and Loss on Valuation of Financial Assets
Santen Announces Share Buyback
Santen Reports Fiscal 2023 Consolidated Performance
Santen and Mitsubishi Tanabe Pharma announce the conclusion of a contract for the joint sales promotion in Japan of Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis
Santen and Bayer Yakuhin Launch Ophthalmic VEGF Inhibitor Eylea®8mg Solution for Intravitreal Injection 114.3 mg/mL
Santen Positioned for Further Growth in China Following Completion of Santen Vision Park
Santen obtains manufacturing and marketing approval in Japan for Alesion® eyelid cream (epinastine hydrochloride), a new treatment for allergic conjunctivitis
Santen Announces Change of Representative Director of the Board
Santen Announces Cancellation of Treasury Shares
Santen Announces Completion of Share Buyback
Notice of Corporate Officer Changes
Santen Announces Status of Share Buyback
Eyedrops for slowing the progression of myopia: Santen files application for manufacturing and marketing approval STN1012700 / DE-127 (atropine sulfate hydrate ophthalmic solution) in Japan
Revision of Dividend Forecast
Santen Reports the 3rd Quarter Fiscal 2023 Consolidated Performance
Santen Announces Status of Share Buyback
Japan Approval Obtained for Ophthalmic VEGF inhibitor Eylea®8mg Solution for Intravitreal Injection 114.3 mg/mL
Santen Announces Status of Share Buyback
Santen Announces Status of Share Buyback
Santen Receives European Commission Approval for Catiolanze® (cationic emulsion of latanoprost 50μg/mL) for Lowering of Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension
Santen Reports the 2nd Quarter Fiscal 2023 Consolidated Performance
Santen Announces Status of Share Buyback
Santen Announces Status of Share Buyback
Revision of Full-Year Earnings Forecasts
Santen Publishes its Annual Integrated Report “Santen Report 2023”
Notice Regarding Implementation of an Early Retirement Program
Santen Announces Status of Share Buyback
Santen Reports the 1st Quarter Fiscal 2023 Consolidated Performance
Santen Announces Status of Share Buyback
Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration and Restricted Stock Unit Plans
Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America
Corporate Governance Report
Santen Announces Status of Share Buyback
Notice of Corporate Officer Changes
Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration and Restricted Stock Unit Plans
Santen Announces Status of Share Buyback
Notice of Board of Director and Corporate Auditor Nominations
Santen Announces Share Buyback
Recording of Extraordinary Losses in Non-consolidated Financial Results
Santen Reports Fiscal 2022 Consolidated Performance
Revision of Full-Year Earnings Forecasts
Santen Announces New Medium-Term Management Plan (FY2023-FY2025)
Santen Files for Manufacturing and Marketing Approval for STN1011402 (Epinastine Hydrochloride) Ophthalmic Cream in Japan - Applied once daily to periocular area, new formulation for treatment of allergic conjunctivitis-
Santen Announces Completion of Share Buyback and Number of Shares to be Canceled
Santen Announces Cancellation of Treasury Shares
Notice of Corporate Officer Change
Santen Announces Status of Share Buyback
Santen Announces China NMPA Acceptance of STN1011101 Marketing Authorization Application in Patients with Open-Angle Glaucoma or Increased Intraocular Eye Pressure
Revision of Full-Year Earnings Forecasts
Santen Reports the 3rd Quarter Fiscal 2022 Consolidated Performance
Santen Announces Status of Share Buyback
Santen Announces Status of Share Buyback
Santen Announces Status of Share Buyback
Notice of Personnel Changes
Santen launches the dry-eye treatment DIQUAS® LX Ophthalmic Solution 3% in Japan - Improved formulation to reduce administration frequency to three-times daily, thus easing patients' burden -
Santen Reports the 2nd Quarter Fiscal 2022 Consolidated Performance
Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts
Santen Announces Share Buyback
Santen Strengthens Global Product Supply Base with Completion of Third Building on Site of Shiga Product Supply Center
Santen Publishes its Annual Integrated Report "Santen Report 2022"
Santen filing accepted by European Medicines Agency (EMA) for review of application for marketing authorization of the use of STN1013001 cationic emulsion of latanoprost 50?g/mL in glaucoma
Santen Announces Cancellation of Treasury Shares
Ophthalmic VEGF inhibitor Eylea® Solution for Intravitreal Injection 40 mg/mL obtains approval for ROP as sixth indication
Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Corporate Governance Report
Notice of Personnel Change
Santen Announces Change of Representative Director of the Board (change in CEO)
Santen Announces Completion of Share Buyback
Santen Announces Status of Share Buyback
Santen Reports the 1st Quarter Fiscal 2022 Consolidated Performance
Santen Announces Status of Share Buyback
Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Santen Announces Status of Share Buyback
Santen Announces Endorsement of Task Force on Climate-Related Financial Disclosures (TCFD)
Corporate Governance Report
Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Santen receives manufacturing and marketing approval for the dry-eye treatment DIQUAS LX Ophthalmic Solution 3% in Japan - Improved formulation to reduce administration frequency to three-times daily, thus easing patients' burden -
Santen and UBE announces U.S. Food and Drug Administration accepts resubmission of NDA for STN1011700 / DE-117 (omidenepag isopropyl) for treating glaucoma and ocular hypertension
Santen Announces Status of Share Buyback
Santen and ActualEyes start registering patients to participate in Phase II clinical trial (Phase IIa / PoC study, PHANTOM study) for Fuchs endothelial corneal dystrophy
Santen Announces Change of Representative Director of the Board and Board of Director and Corporate Auditor Nominations
Santen Received the Approval of Verkazia (Ciclosporin Eye Drops (III)), Providing New Solutions for Severe Vernal Keratoconjunctivitis in China
Santen Announces Share Buyback
Notice on the Formulation of a Share Buyback Policy
Notice regarding Cancellation of 'Transition to a Holding Company Structure through Sole-share Transfer and Change in Fiscal Year'
Santen Reports Fiscal 2021 Consolidated Performance
Santen's Verkazia (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States
Santen Announces Change of Major Shareholder
Santen Announces Change of Representative Director of the Board
Santen to Present Latest Data on Omidenepag Isopropyl at AGS 2022
Santen Wins Award for Excellence at the "Nikkei Integrated Report Award 2021"
Santen Receives Marketing Approval in Japan for "PRESERFLO MicroShunt Glaucoma Drainage System Core Kit" to Treat Glaucoma
Reinventing of Our Leadership Team to Shape the Future of Santen
Santen certified as Digital Transformation Business Operator by Ministry of Economy, Trade and Industry
Santen Reports the 3rd Quarter Fiscal 2021 Consolidated Performance
Santen and Aerie to accelerate global deployment of Rhopressa/Rhokiinsa and Rocklatan/Roclanda Expanding the area of exclusive licensing, including Europe and China
Corporate Governance Report
Santen and ActualEyes sign a joint development agreement on Phase II clinical trial (Phase II a / PoC study) for a treatment candidate for Fuchs endothelial corneal dystrophy
Santen to Present Latest Data on Omidenepag Isopropyl at AAO 2021
Santen Reports the 2nd Quarter Fiscal 2021 Consolidated Performance
Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil Ophthalmic Solution 0.02% Phase 3 Clinical Trial in Japan
Santen to Present Latest Data on STN2000100 (DE-128, MicroShunt) at 39th ESCRS
Notice of Corporate Officer Appointments
Singapore National Eye Centre and Santen Announce a Strategic Partnership to Develop and Deploy Internationally an Innovative Educational Programme for Development of the Eye Care Ecosystem in Asia
Notice on the Completion of Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration System
Integrated Report Santen Report 2021 has been published
Santen to Present Latest Data including STN1012700 (DE-127) at APAO 2021
Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration System
Notice on the Selection to Apply to New Market Segment 'Prime Market' on the Tokyo Stock Exchange
Santen and Airdoc Partner to Improve Diagnostic Rate of Fundus Ocular Diseases with AI device in China
Santen Files for Manufacturing and Marketing Approval of STN1008903 (diquafosol sodium) - Improved formulation to reduce the frequency of administration to ease patients' burden -
Santen and Sydnexis execute an exclusive licensing agreement for SYD-101, a novel investigational treatment for progressive childhood myopia
Santen Reports the 1st Quarter Fiscal 2021 Consolidated Performance
Santen to Present Latest Data including STN1012700 (DE-127) and STN1007603 (DE-076C) at 33rd APACRS 2021 meeting
Santen and IAPB taking action to implement the first ever UN General Assembly resolution recognizing the link between eye health and sustainable development
Santen to Present Latest Data on STN2000100 at 2021 ASCRS Annual Meeting
Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Santen's CO2 emission reduction targets endorsed by the Science Based Targets (SBT) initiative
Corporate Governance Report
Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Santen to Present Latest Data on STN2000100 at COS 2021 and 9th WGC
Santen Receives U.S. FDA Approval for Verkazia (Cyclosporine Ophthalmic Emulsion, 0.1%) for the Treatment of Vernal Keratoconjunctivitis in Children and Adults
Santen to Present Latest Data on Omidenepag Isopropyl at APGC 2021
Santen and Glaukos Enter into a New Collaboration in the Development and Commercialization of STN2000100 (DE-128) in the Americas, Australia, and New Zealand
Santen Announces Medium-Term Plan "MTP2025"
Santen Establishes "Santen Vision for the Earth 2050" Setting Environmental Targets for 2030, Including CO2 Emissions Reduction Targets
Santen expresses a stance to strengthen its gender diversity. -Joining the "30% Club Japan," taking action to increase gender diversity at board and senior management -Becoming a signatory of the "UN Women's Empowerment Principles" promoting gender equali
Notice of Board of Director and Corporate Auditor Nominations
Santen Reports Fiscal 2020 Consolidated Performance
Notice of Postponement of Transition to a Holding Company Structure through Sole-share Transfer and Change in Fiscal Year
Santen has commenced the construction of the new factory in Suzhou to address expanding product demand in China -Toward reinforcing global production and supply structure-
Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts
Notice of Corporate Officer Appointments
Santen Announces Sponsorship of IBSA Blind Football World Grand Prix for the Second Consecutive Year
(Timely Disclosure) Notice of Commencement of Preparation for Transition to a Holding Company and Change in Fiscal Year
Santen Reports the 3rd Quarter Fiscal 2020 Consolidated Performance
Santen and Ube Announces U.S. FDA Acceptance of New Drug Application for STN10117 (DE-117) (JAN: Omidenepag Isopropyl) as a Treatment for Patients with Glaucoma and Ocular Hypertension
Santen and Ube Announces Launch of Glaucoma and Ocular Hypertension Treatment EYBELIS Ophthalmic Solution 0.002% in South Korea
Santen to Hold a Presentation for the 39th Annual J.P. Morgan Healthcare Conference
Santen Joins the Valuable 500 International Initiative Promoting the Active Participation of People with Disabilities
Santen to Present Latest Data on Omidenepag Isopropyl and Microshunt at AAO 2020 Virtual
Santen Reports the 2nd Quarter Fiscal 2020 Consolidated Performance
Santen releases LENTIS Comfort Toric in Japan, a multifocal IOL covered under the Japanese health insurance program for cataract patients with astigmatism
Santen, JBFA and IBF Foundation Form Long-term Partnership for an Inclusive Society ~An innovative, 10-year partnership agreement that aims to achieve long-term stability of sports management for the advancement of diversity and inclusion in our society~
Santen and Aerie Conclude Exclusive License Agreement for Rhopressa and Rocklatan in Japan and Several Other Asian Countries
Notice on the Establishment of Holding Company in China
Santen and Orbis International Announce Long-term Partnership to Tackle the Increasing Burden of Eye Diseases
Santen and U.S. Ophthalmic Company Eyevance Enters into Share Purchase Agreement
Notice of Corporate Officer Appointments
Santen Reports the 1st Quarter Fiscal 2020 Consolidated Performance
Santen and RVL Pharmaceuticals, Inc., an Osmotica Company, Enter into an Exclusive License Agreement in Japan, Asia, and EMEA for RVL-1201, a First-in-Class Treatment for Acquired Blepharoptosis
Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Santen Introduces its New Corporate Brand Name Notation and Corporate Slogan Aiming to Grow on a Globally, Going beyond the Pharmaceutical Industry
Announcement of New Vision Aiming to Resolve Social Issues Related to the Eye Health of People around the World
Santen Announces U.S. FDA Acceptance of Premarket Approval (PMA) Application for DE-128 (MicroShunt) for Review
Corporate Governance Report
Santen and Singapore's Health-tech Start-up, Plano Form a Strategic Alliance to Tackle the Global Burden of Myopia
Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Santen and Orbis International Join Forces to Expand Access to Training for Eye Care Professionals through Telemedicine Platform
Providing Eye Care Information to Resolve Problems Caused by Excessive Screen Time
Bayer Yakuhin and Santen launch 'EYLEA Intravitreal Injection KIT 40mg/mL', pre-filled syringe of intravitreal VEGF Inhibitor EYLEA
Notice of Board of Director and Corporate Auditor Nominations
Santen Reports Fiscal 2019 Consolidated Performance
Santen and jCyte Conclude an Exclusive Licensing Contract in Japan, Asia and Europe for the jCell Therapy Program for Retinitis Pigmentosa
Santen, Together with Nonprofit Organization, Japan Blind Football Association, to Support People with Visual Impairments Facing the COVID-19 Pandemic
Santen Introduces Eco-Friendly Biomass Plastic Eyedrop Bottles
Intravitreal VEGF Inhibitor EYLEA approved as a Treatment of Neovascular Glaucoma (NVG), its fifth indication
Notice of Corporate Officer Appointments
Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration
Santen to Conduct Activities to Raise Awareness on Importance of Early Detection and Treatment of Glaucoma during World Glaucoma Week (March 8-14, 2020)
Notice of personnel change
Santen and Verily Establish Joint Venture to Develop and Commercialize Unique Ophthalmic Devices
Santen Reports the 3rd Quarter Fiscal 2019 Consolidated Performance
Santen Pharmaceutical Selected as Title Sponsor of IBSA Blind Football World Grand Prix 2020!
Santen Pharmaceutical Signs Partnership Agreement with ITU Supporting ITU and WHO initiative 'Be He@lthy, Be Mobile' in Ophthalmology
Santen Announces the Construction of China Second Plant
Santen Announces Topline Result from Phase II Clinical Trial of DE-127 for Patients with Mild and Moderate Myopia
Bayer Yakuhin and Santen Pharmaceutical extend co-promotion agreement for Eylea (aflibercept intravitreal injection) in Japan
Launch of Alesion LX Ophthalmic Solution 0.1% in Japan
Santen Reports the 2nd Quarter Fiscal 2019 Consolidated Performance
Santen Announces Proposed Dividend Change
Santen Donates to the Disaster Caused by Typhoon Hagibis
Receipt of NDA Approval of Alesion LX for anti-allergy in Japan, and Joint Sales Promotion Contract with Mitsubishi Tanabe Pharma
Sponsorship Agreement for IBSA Blind Football Asian Championships 2019 signed between Santen, IBF Foundation, and JBFA
Santen Announces Topline Pivotal Data for DE-128 (MicroShunt) Demonstrating Reductions in Intraocular Pressure and Medication Use in Patients
Santen Reports the 1st Quarter Fiscal 2019 Consolidated Performance
Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Corporate Governance Report
Santen Included in All Four ESG Investment Indices Selected by GPIF
R&D collaboration and Option & Licence Agreement with Oxford Biomedica for development of gene therapy vectors for inherited retinal disease
Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Santen Chooses SAP S/4HANA Cloud and Other SAP Solutions to Reform Key Operation System and Strengthen Global Management Structure
Notice of Board of Director and Corporate Auditor Nominations
Santen Reports Fiscal 2018 Consolidated Performance
Santen and Glaukos Enter into Collaboration and Distribution Agreement for Exclusive Distribution of the MicroShunt (DE-128) in the United States
Santen Announces Launch of LENTIS Comfort, Low-Add Segmental Intraocular Lens for Cataract Treatment in Japan
Santen Announces Cancellation of Treasury Shares
Santen Announces Completion of Repurchase of Own Shares
Notice of Corporate Officer Appointments
Santen to Conduct Activities to Raise Disease Awareness during World Glaucoma Week, March 10 to 16
Santen Selected and Launches Gene Therapy Drug Research and Development Project for Inherited Ocular Disease Treatment for CiCLE Program
Santen Selected and Launches Photo-Crosslinking Research and Development Project for Pathologic Myopia Treatment for CiCLE Program
Santen Announces Status of Repurchase of Own Shares
Santen Announces Repurchase of Own Shares
Santen Reports the 3rd Quarter Fiscal 2018 Consolidated Performance
Santen Hosts Event to Raise Public Awareness of Importance of Continued Glaucoma Treatment Prior to Sponsoring World Glaucoma Week in March
Santen's Tampere manufacturing facility to be acquired by NextPharma
Santen Updates Pipeline in Corporate Presentation of January 8, 2019
Santen and Ube Industries Announce Launch of Glaucoma and Ocular Hypertension Treatment EYBELIS Ophthalmic Solution 0.002% in Japan
Corporate Governance Report
Santen Reports the 2nd Quarter Fiscal 2018 Consolidated Performance
Santen Donates to the 2018 Hokkaido Eastern Iburi Earthquake Relief Efforts in Japan
Santen Announces Drug Discovery and Development Agreement with PeptiDream
Santen Files for Manufacturing and Marketing Approval of Anti-Allergy Ophthalmic Drug Candidate DE-114A (JAN: Epinastine Hydrochloride)
Santen and Ube Industries Announce Receipt of Manufacturing and Marketing Approval for Glaucoma and Ocular Hypertension Treatment EYBELIS in Japan
Personnel Changes of Corporate Officer
Personnel Changes of Representative Director of the Board
Santen Reports the 1st Quarter Fiscal 2018 Consolidated Performance
Notice on Completion of Payment for Issuance of New Shares Under Restricted Stock-linked Remuneration Program
Santen Donates to Japan Flood and Landslide Relief Efforts
Santen Receives Marketing Authorisation from the European Commission for DE-076C (Verkazia) as an Orphan Medicinal Product
Corporate Governance Report
Notice on the Issuance of New Shares Under Restricted Stock-Linked Remuneration Program
Santen Announces Medium-Term Plan (MTP2020)
Santen Reports Fiscal 2017 Consolidated Performance
Notice of Board of Director and Corporate Auditor Nominations
Notice on the Introduction of a New Stock-Linked Remuneration Program and Change to Director Remuneration
Notice of Corporate Officer Appointments
Santen to Conduct a Public Awareness Campaign for Glaucoma During World Glaucoma Week March 11 - 17
Santen Announces Appointment of New President
Santen Reports the 3rd Quarter Fiscal 2017 Consolidated Performance
Santen Receives Complete Response Letter from U.S. FDA for Intravitreal Sirolimus (DE-109)
Santen Files for Manufacturing and Marketing Approval of Glaucoma and Ocular Hypertension Drug Candidate DE-117 (JAN: Omidenepag Isopropyl)
Santen Reports the 2nd Quarter Fiscal 2017 Consolidated Performance
Santen Announces Approval of Diquas for the Treatment of Dry Eye in China
Santen Selected as a Member of Dow Jones Sustainability Asia Pacific Index, an Index for Socially Responsible Investment
Notice on Details of Subscription Rights to New Shares(Stock Options for Stock-Linked Remuneration)
Corporate Governance Report
Santen Reports the 1st Quarter Fiscal 2017 Consolidated Performance
Santen to Grant Subscription Rights to New Shares as Stock Options for Stock-Linked Remuneration
Santen Receives Positive CHMP Opinion in Europe for Ciclosporin eye drops for the Treatment of Paediatric Patients with Severe Vernal Keratoconjunctivitis
Santen and TRACON Announce Initiation of a Phase 2a Study of DE-122 for the Treatment of Wet Age-Related Macular Degeneration
(Correction) Corporate Governance Report
Corporate Governance Report
Notice of Board of Director and Corporate Auditor Nominations
Santen Reports Fiscal 2016 Consolidated Performance
Santen Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for Intravitreal Sirolimus (DE-109) in the Treatment of NIU-PS
Santen Announces Strategic Investment in Regenerative Patch Technologies LLC
Santen and Japan Blind Football Association (JBFA) Enter Partnership
Notice of Corporate Officer Appointments
SANTEN AND SINGAPORE EYE RESEARCH INSTITUTE (SERI) ANNOUNCE AN EXPANDED RELATIONSHIP INCLUDING THE CREATION OF A NEW JOINT LABORATORY TO DEVELOP NOVEL OPHTHALMIC THERAPEUTICS, DIAGNOSTICS AND DEVICES
Santen Reports the 3rd Quarter Fiscal 2016 Consolidated Performance
Notice of Change in Significant Shareholder
Notice of Cancellation of Treasury Shares
Santen Announces Phase III SAKURA Program Topline Results in Patients with Non-Infectious Uveitis of the Posterior Segment
Santen Announces Completion of Share Repurchase Program
Santen Reports the 2nd Quarter Fiscal 2016 Consolidated Performance
Santen Announces Status of Repurchase of Own Shares
Santen, RIKEN and FBRI Announce Research Collaboration to Develop New Retinal Disease Treatments
Personnel Changes of Corporate Officer
Santen Announces Status of Repurchase of Own Shares
Santen Announces Repurchase of Own Shares
Notice on Details of Subscription Rights to New Shares (Stock Options for Stock-Linked Remuneration)
Santen Announces the Completion of Establishment Procedures for Chongqing Santen Kerui Pharmaceutical Co., Ltd.
Santen Completes Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device
Santen and University College London to collaborate on ophthalmic research and education
Santen to Grant Subscription Rights to New Shares as Stock Options for Stock-Linked Remuneration
Santen Reports the 1st Quarter Fiscal 2016 Consolidated Performance
Santen to Acquire InnFocus, Developer of MicroShunt Glaucoma Implant Device
Corporate Governance Report
Santen Receives Positive Recommendation from CDSCO for Sirolimus
Vekacia® (Ciclosporin 1mg/mL Eye Drops) Pivotal Trial Meets Primary and Key Secondary Endpoints
Notice of Board of Directors and Corporate Auditor Nominations
Santen Provides Update on EU Marketing Authorization Application for DE-109 (Sirolimus)
Flash Report on FY2015 Financial Results
Santen Enters Licensing Agreement with Ono for FP/EP3 Dual Agonist, ONO-9054
Santen China and Chongqing Kerui Announce Collaboration to Develop New Ophthalmic Joint Venture
Notice of Corporate Officer Appointments
Santen Announces Proposed Dividend Change
Santen Announces Proposed Dividend Change
Notice on the Establishment of Santen Business Services Co., Ltd.
Notice on the Establishment of Santen Business Services Co., Ltd.
Flash Report on the 3rd Quarter of FY2015 Financial Results
"Specialized in Ophthalmology" Santen Presents at J.P. Morgan Conference
Corporate Governance Report
NICE recommends the use of IKERVIS® in England for the treatment of severe keratitis in adult patients with dry eye disease
Santen Announces Financial Result for the Second Quarter ended September 30, 2015
Santen Reports Consolidated Performance For the First Half of FY2015
NICE recommends the use of IKERVIS in England for the treatment of severe keratitis in adult patients with dry eye disease
Notice on Details of Subscription Rights to New Shares (Stock Options for Stock-Linked Remuneration)
Santen Announces Approval of TAPROS for the Treatment of Open-Angle Glaucoma and Ocular Hypertension in China
Santen Announces Financial Result for the First Quarter ended June 30, 2015
Santen to Grant Subscription Rights to New Shares as Stock Options for Stock-Linked Remuneration
Notice of Completion of the Transfer of Anti-Rheumatic Pharmaceutical Business to AYUMI Pharmaceutical Corporation
Santen Launches Ikervis in Germany
TRACON Pharmaceuticals Announces IND Filing of DE-122 (TRC105) for the Treatment of Wet Age-Related Macular Degeneration by Santen Pharmaceutical
Intravitreal VEGF Inhibitor "EYLEA" Approved as a Treatment of Retinal Vein Occlusion(RVO)
Santen Launches COSOPT Mini Combination ophthalmic solution for the Treatment of Glaucoma and Ocular Hypertension
Santen Reports Consolidated Performance for the Fiscal Year Ended March 31, 2015
Santen Announces Assignment of its Anti-Rheumatic Pharmaceuticals Business to Hyperion Pharma Co., Ltd.
Notice of Member of the Board and Corporate Auditors Nominations
Financial Results for the Fiscal Year Ended March 31, 2015
Santen Launches New Sante de U α, an OTC Eye Drop
Santen Announces Approval of Ikervis for EU Marketing Authorization
Revision of consolidated earnings forecasts for FY 2014
Santen Announces Proposed Dividends Change
Santen Announces Approval of Glaucoma and Ocular Hypertension Therapeutic,COSOPT Mini Ophthalmic Solution in Japan
Santen to Co-sponsor "Green Light-Up"to Illuminate Landmark Facilities in Green in Japan during the World Glaucoma Week from March 8, 2015 to March 14, 2015
Santen Announces Stock Split and Amendment to the Articles of Incorporation
Santen receives a Positive CHMP Opinion for EU Marketing Authorization for Ikervis®
Santen Launches TAPCOM Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension
Intravitreal VEGF Inhibitor "EYLEA" Obtains Additional Indication of Diabetic Macular Edema (DME), its Fourth Indication
Santen and Singapore Eye Research Institute (SERI) Announce a Collaboration to Develop New Ophthalmic Therapeutics
Santen Receives Financing from the Development Bank of Japan based on "DBJ Environmental Rating"
Santen Announces Closing of Asset Purchase Agreement with Respect to Acquisition of Ophthalmology Assets from Merck
Increase of Capital for a Consolidated Subsidiary in Europe
Intravitreal VEGF Inhibitor "EYLEA" Obtains Additional Indication of Myopic Choroidal Neovascularization (mCNV)
Eyestrain Common Issue Caused by Contact Lenses!? Santen Launches Soft Santear Hitomi Stretch, an Eye Drop for Use with Soft Contact Lenses to Reduce Eyestrain by Relaxing Ciliary Muscle Stiffness Which Can Be a Cause of Eyestrain
Notice on Details of the Rights to Subscribe for New Shares (Stock Options as Stock-Linked Remuneration)
Santen Files for Manufacturing/Marketing Approval of its Glaucoma and Ocular Hypertension Therapeutic, COSOPT Mini Combination Ophthalmic Solution
Santen to Grant Rights to Subscribe for New Shares as Stock Options as Stock-Linked Remuneration
Medium-Term Management Plan FY2014-2017
Changes in Significant Shareholders
Santen Announces Closing of Asset Purchase Agreement with Respect to Acquisition of Ophthalmology Assets from Merck
Notice of the Nominations for the Member of the Board
Santen Announces Financial Results for the Year ended March 31, 2014
Santen Announces the Signing of Agreement between Merck for the Purchase of Assets in Ophthalmology
Santen Phase III Study Meets Primary Endpoint for The treatment of Non-Infectious Posterior Segment Uveitis (NI-PSU)
Santen Partners with Akorn, Inc. subsidiary Oak Pharmaceuticals for Marketing of Tafluprost, the Treatment of Glaucoma and Ocular Hypertension in the U.S.
The Osaka Study: An epidemiological survey showing that dry eye disease lowers work productivity, affects quality of life and correlates with metabolic syndrome
Notice of the appointment of Corporate Officers
Santen and TRACON Announce Agreement for the Development and Commercialization of TRC105 in Ophthalmology
Changes in Significant Shareholders
Santen Pharmaceutical Voluntarily Adopts International Financial Reporting Standards (IFRS)
Revision of consolidated earnings forecasts for FY 2013
Notice on the Establishment of Subsidiary in Singapore
European marketing authorization application for Ikervis has been filed to the EMA for the treatment of Dry Eye Disease
Santen to Support People in the Philippines Affected by Typhoon Haiyan through Donations
Santen Launches Alesion® 0.05% Ophthalmic Solution for Allergic Conjunctivitis Treatment in Japan
Intravitreal VEGF Inhibitor "EYLEA" Obtains Additional Indication of Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
Announcing the Opening of the Ho Chi Minh Representative Office
Santen Announces the Launch of TAPROS MINI Ophthalmic Solution 0.0015% for Glaucoma and Ocular Hypertension
Santen Announces Approval of Alesion® 0.05% Ophthalmic Solution for Allergic conjunctivitis Treatment in Japan
Santen Announced Approval for TAPCOM Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension
Notice on Details of the Rights to Subscribe for New Shares(Stock Options as Stock-Linked Remuneration)
Santen Grants Rights to Subscribe for New Shares as Stock Options
Name Change of European Subsidiary
Santen to issue Stock Option to Directors as Stock-Linked Remuneration
Notice Concerning Abolition of Retirement Benefit Program for Directors
Notice of the Nomination for Members of the Board of Directors
Discontinuance and Abolition of Countermeasures to Large-Scale Purchases of the Corporation's Shares (Takeover Defense Measures)
Notice of the appointment of Corporate Officers
Santen announced the launch of Eternity Natural Uni and Accuject UniFit, a novel acrylic intraocular lens and its dedicated injector system
Santen Announces Approval of TAPROS MINI Ophthalmic Solution 0.0015% for Glaucoma and Ocular Hypertension Treatment in Japan
Changes in Significant Shareholders
Santen Files for Manufacturing/Marketing Approval of its Anti-Allergic Ophthalmic Solution DE-114 (Generic name: Epinastine Hydrochloride)
Intravitreal VEGF Inhibitor "EYLEA (aflibercept) Solution for Intravitreal Injection" Released on the Market for the Treatment of Wet Age-Related Macular Degeneration
Notice of Cancellation of Treasury Shares
Santen to Renew the Sante 40 OTC Eye Drop Series
Intravitreal VEGF Inhibitor "EYLEA Solution for Intravitreal Injection" and "EYLEA Intravitreal Injection KIT" Approved for the Treatment of Wet Age-Related Macular Degeneration in Japan
Notice on the Establishment of a New Sales and Marketing Company in China
Eisai and Santen Enter into Option Agreement for New Ophthalmic Drugs
Notification Regarding Result and Completion of Acquisition of Treasury Stock and Tender Offer of Treasury Stock
Notice of Acquisition and Tender Offer of Treasury Stock
Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)
FDA Approves enVista, a Single-Piece Intraocular Lens, Made from the Glistening-Free, Hydrophobic, Acrylic Material Developed by AVS
Notice on the Allotment of Stock Options (Stock Acquisition Rights)
Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Directors
Announcement of the conclusion of the agreement on co-promotion of VEGF Trap-Eye (aflibercept intravitreal injection)
Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Corporate Officers
Notice of the Nominations for the members of the Board of Directors
Notice of the appointment of Corporate Officers
Santen to Launch Sante Medical Guard OTC Eye Drop
FDA Approves ZIOPTAN (tafluprost ophthalmic solution),Merck's Once-Daily, Preservative-Free Ophthalmic Medication
Notice on the Establishment of Holding Company in Europe
Santen to Launch Nutritional Supplement Sante Lutax 20 + DHA
Santen to Retire Treasury Stock [PDF:17KB]
Santen's Noto Plant Obtains Certification of ISO 14001 [PDF:17KB]
Implementation of a squeeze-out on the shares of Novagali Pharma SA initiated by Santen Pharmaceutical Co., Ltd.
Mise en œuvre par Santen Pharmaceutical Co., Ltd. de la procédure de retrait obligatoire portant sur les actions de Novagali Pharma SA
Notice on Board of Directors
Santen to Issue Stock Acquisition Rights for the Purpose of Granting Stock Options [PDF:20KB]
Succès de l'offre publique d'achat simplifiée de Santen Pharmaceutical Co., Ltd. sur les actions et les bons desouscription d'actions de Novagali Pharma SA
Notice of a successful result of the Simplified Cash Tender Offer for the Shares and bons de souscription d'actions of Novagali Pharma SA by Santen Pharmaceutical Co., Ltd.
Santen Pharmaceutical Co., Ltd. completes the acquisition of a controlling interest in Novagali Pharma S.A.
Ouverture de l'offre publique d'achat simplifiée
Informations Relatives aux Caractéristiques, Notamment Juridiques, Financieres et Comptables de la Societe Santen Pharmaceutical Co., Ltd.
Mise à disposition de la note d'information relative à l'offre publique d'achat simplifiée sur Novagali Pharma SA et des informations relatives aux caractéristiques notamment juridiques, financières et comptables de Santen Pharmaceutical Co., Ltd.
The Offer Document relating to the Simplified Cash Tender Offer for the Shares and Warrants of Novagali Pharma S.A. by Santen Pharmaceutical Co., Ltd.
Note d'information de la societe Santen Pharmaceutical Co., Ltd.
Dépôt d'une offre publique d'achat simplifiée
Filing of a Draft Simplified Cash Tender Offer regarding Novagali Pharma SA
Offer Publique D'achat Simplifyée
Santen Announces Financial Result for the Second Quarter ended September 30, 2011
Ube and Santen Announce License and Collaboration Agreement for EP2 Agonist
Announcement of the Year-end Dividends
Medium Term Management Plan FY2011-2013
Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Directors
Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Corporate Officers
Notice of the Nominations for the Member of the Board
Signing of an agreement with respect to an acquisition of a controlling interest in Novagali Pharma S.A. by Santen Pharmaceutical Co., Ltd.
Notice on the Establishment of Subsidiary in India
Santen Announces Financial Result for the First Quarter ended June 30, 2011
Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)
Notice on the Allotment of Stock Options (Stock Acquisition Rights)
Santen Launches Broad-spectrum Antibacterial Ophthalmic Solution Cravit Ophthalmic Solution 1.5%
Santen Announces Financial Results for the Year ended March 31, 2011
Announcement regarding Recall of OTC Eye Drop Product
Santen Inc. Head Office Relocation
Notice of the change of Corporate Officer
Effect of the Tohoku-Kanto Earthquake on Santen
Notice of Donation with regards to the Tohoku-Kanto Earthquake
Notice of the appointment of Corporate Officers
Notice Concerning Changes in Status of Major Shareholders After Disposal of Treasury Stock Through Third-Party Allotment
Notice Concerning Execution of Business and Capital Alliance Agreement and Disposal of Treasury Stock Through Third-Party Allotment
Santen Announces Financial Result for the Third Quarter ended December 31, 2010
Santen Launches DIQUAS Ophthalmic Solution 3% for Dry Eye Treatment in Japan
Santen Announces Financial Results for the Year ended March 31, 2009
Santen Announces Financial Result for the Second Quarter ended September 30, 2010
Reorganization of manufacturing function and transfer of Osaka plant
Santen Announces Financial Result for the First Quarter ended June 30, 2010
Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)
Notice on the Allotment of Stock Options (Stock Acquisition Rights)
Banyu and Santen Launch COSOPT® Combination Ophthalmic Solution: Glaucoma and Ocular Hypertension Drug
Renewal of the Countermeasures to Large-Scale Purchases of the Corporation's Shares (Takeover Defense Measures)
Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Corporate Officers
IR News Notice of the Change of Representative Director and the Nominations for the Members of the Board of Directors
Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Directors
Santen Launches Glaucoma and Ocular Hypertension Treatment TAFLOTAN® in Korea
Clinical Data, Inc. Licenses Adenosine A2A Agonist to Santen for Development of Ophthalmic Treatments
Santen Announces Approval of DIQUAS for Dry Eye Treatment in Japan
MHLW Grants Approval for COSOPT Combination Ophthalmic Solution
Change of management positions at Santen Inc.
Notice of the appointment of Corporate Officers
Santen Files Manufacturing/Marketing Approval of its Broad Spectrum Anti-Infective Ophthalmic Solution DE-108 (Generic name: Levofloxacin, high concentration)
Banyu and Santen Announce Co-Promotion Agreement for Combination Ophthalmic Solution, Treatment for Glaucoma and Ocular Hypertension
Santen Announces Financial Result for the Third Quarter ended December 31, 2009
Revision of Financial Forecast
Santen Announces Financial Result for the Second Quarter ended September 30, 2009
Santen Announces Financial Result for the First Quarter ended June 30, 2009
Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)
Notice on the Allotment of Stock Options (Stock Acquisition Rights)
Santen to Issue Stock Acquisition Rights to the Directors for the Purpose of Granting Stock Options
Santen to Issue Stock Acquisition Rights to the Corporate Officers for the Purpose of Granting Stock Options
Santen Announces Financial Results for the Year ended March 31, 2009
Santen and Merck & Co., Inc Sign Licensing Agreement for Tafluprost, Treatment for Glaucoma and Ocular Hypertension
Santen Announces Financial Result for the Second Quarter ended September 30, 2008
Santen Announces Approval of TAPROS™ for Glaucoma and Ocular Hypertension Treatment in Japan
Revision of Performance Forecast
Santen Announces Financial Result for the First Quarter ended June 30, 2008
Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)
Notice on the Allotment of Stock Options (Stock Acquisition Rights)
Santen Files Manufacturing and Marketing Approval for Corneal and Conjunctival Epithelial Disorder Treatment
Santen and MacuSight Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions
Santen to Issue Stock Acquisition Rights to the Directors for the Purpose of Granting Stock Options
Santen to Issue Stock Acquisition Rights to the Corporate Officers for the Purpose of Granting Stock Options
Extension of Nara Research and Development Center
Notice on Board of Directors, Corporate Auditors and Corporate Officers
Santen Oy Receives Marketing Authorization for its Glaucoma and Ocular Hypertension Treatment, TAFLOTAN® in Denmark
Notice Regarding the Completion of Purchase of the Company's Own Shares in the Market
Notice Regarding the Purchase of the Company's Own Shares in the Market
Santen to Lift Condition for Approval of PAPILOCK Mini Ophthalmic Solution 0.1%
Santen to Purchase Own Shares
Santen Announces Financial Result for the Third Quarter ended December 31, 2007 Appendix
Santen to Launch Nutritional Supplement Sante Lutax
Santen to Redesign Sante de U Plus E Alfa Package
Santen Announces Financial Result for FY2007 First Quarter
Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)
Notice on the Allotment of Stock Options (Stock Acquisition Rights)
Resolution Notice of The 95th Annual General Meeting of Shareholders
Convocation Notice of the 95th Annual General Meeting of Shareholders
Santen Announces Financial Results for the Year ended March 31,2007
Introduction of Takeover Defense Measures
Santen to Launch Sante Uruoi Contact a
Santen Oy Submits Marketing Approval for Glaucoma and Ocular Hypertension Drug Candidate DE-085
Santen Opens its Shenyang Representative Office
Noto Plant Product Line to Resume
Impact of Noto Peninsula Earthqauke, Ishikawa Prefecture
Santen Announces Proposed Dividends Change
Changes in Significant Shareholder
Santen Announces Financial Result for the Third Quarter ended December 31, 2006
Santen Global Portal Open
Santen to Launch Sante AL Cool II
Santen Announces Financial Results for the First Six Months ended September 30, 2006 [PDF:16KB]
Santen to Launch OTC Eye Drops Sante Medical 10
Santen Files for Manufacturing and Marketing Approval for its Glaucoma and Ocular Hypertension Drug Candidate DE-085 (INN: Tafluprost)
Santen Announces Financial Result for the First Quarter ended June 30, 2006
2006-2010 Medium-term Management Plan
Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)
Notice on the Allotment of Stock Options (Stock Acquisition Rights)
Change in Issuance of Right to Subscribe for New Shares as Stock Options for Directors
Santen to Issue Stock Acquisition Rights to the Directors
Santen Announces Financial Results for the Year ended March 31,2006[PDF:16KB]
Announcement of Change of Representative Directors
Agreement Concerning Microsphere-based Platform Development and License
Licensing Agreement on PDE4 Inhibitor ONO-6126
Agreement Concerning Joint Research of Ophthalmic drug
Santen Announces Preliminary Results of Overseas Clinical Trials of Two Glaucoma Drug Candidates
Santen Announces Financial Result for the Third Quarter of Fiscal Year 2005 (Nine months ended December 31, 2005)
Santen Announces Financial Result for the Third Quarter of Fiscal Year 2005( Nine months ended December 31, 2005)
Santen Launches PAPILOCK Mini Ophthalmic Solution 0.1%
Santen Announces Financial Results for the First Six Months ended September 30, 2005[PDF:17KB]
Santen Receives Manufacturing and Marketing Approval for its Vernal Keratoconjunctivitis Treatment, PAPILOCK Mini Ophthalmic Solution 0.1%[PDF:39KB]
Santen Establishes Subsidiary in China[PDF:29KB]
Agreement Concerning CS-011 as Dry Eye Drug Candidate[PDF:18KB]
Santen to Outsource its Logistics Operations [PDF:17KB]
Santen's Car Including PC and Roster with Private Information Stolen[PDF:16KB]
Financial Results for the First Quarter and Forecasts for FY2005 (Year ending March 2006)[PDF:500KB]
Santen Announces Financial Results for the First Quarter of Fiscal Year 2005. (Three Months Ended June 30,2005)[Report]
Santen Opens its Shanghai Representative Office [PDF:18KB]
Notice on the Exercise Price of Stock Options (Stock Acquision Rights)[PDF:16KB]
Notice on the Allotment of Stock Options (Stock Acquisition Rights)[PDF:16KB]
Announcement on the New Management Organization [PDF:22KB]
Santen to Issue Stock Acquisition Rights for the Purpose of Granting Stock Options [PDF:20KB]
Santen to Issue Stock Acquisition Rights to the Directors for the Purpose of Granting Stock Options
Santen Announces Financial Results for the Year ended March 31, 2005[PDF:19KB]
Santen set up retirement benefit trust [PDF:17KB]
Nara Institute of Science and Technology and Santen conclude agreement to establish Collaborative Course[PDF:31KB]
Santen Announces Proposed Dividends Change [PDF:17KB]
Santen Announces Financial Result for the Third Quarter of Fiscal Year 2004 ( Three Months Ended December 31, 2004) [Report]
Santen Purchase Own Shares on Market by ToSTNet-2[PDF:16KB]
Santen to Purchase Own Shares on Market by ToSTNet-2[PDF:18 KB]
Santen to Terminate Sales of Ophthalmic Surgical Instruments
Santen Announces Financial Results for the First Six Months ended September 30, 2004
Santen Establishes New Retirement Benefit and Pension Program[PDF:35KB]
Agreement Concerning Development of Novel Anti-rheumatic Agent Anti-APO-1 Antibody in Japan [PDF:38KB]
Annual Report 2004 is now available on this Web site.
Santen Announces Financial Results for the First Quarter of Fiscal Year 2004 (Three Months Ended June 30, 2004)[Report]
Santen Launches Anti- rheumatic METOLATE® Tablets 2mg [PDF:16KB]
Agreement Concerning Glaucoma and Ocular Hypertension Treatment RESCULA® Eye Drops[PDF:22KB]
Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)[PDF:15KB]
Santen Hosts the 92nd Annual General Meeting of Shareholders
Notice on the Allotment of Stock Options (Stock Acquisition Rights)[PDF:12KB]
Santen Announces Financial Results for the Year ended March 31, 2004 [PDF:57KB]
Santen to Retire Treasury Stock [PDF:12KB]
Revision of Performance Forecast [PDF:16KB]
Santen Announces Proposed Dividends Change [PDF:13KB]
Santen Receives FDA Approval of IQUIX, New Treatment for Sight-threatening Condition [PDF:19KB]
Santen Announces Financial Results for the Nine Months Ended December 31, 2003
Santen Reorganizes Domestic Sales Operation [PDF:14KB]
Santen Signs Agreement With Johnson & Johnson Vision Care, Inc. To Supply Prescription Ophthalmic Products [PDF:18KB]
Santen Announces Financial Results for the First Six Months ended September 30, 2003 [PDF:15KB]
Santen Announces Closure of its U.S. Subsidiary, Phacor Inc. [PDF:15KB]
Santen Files for Manufacturing Approval for its Vernal Keratoconjunctivitis Treatment, Ciclosporin Ophthalmic Solution [PDF:19KB]
Santen Announces Financial Results for the First Quarter of Fiscal Year 2003 (Three Months Ended June 30, 2003)
Santen Hosts the 91st Annual General Meeting of Shareholders
Notice of the 91st Annual General Meeting of Shareholders [PDF:60KB]
Santen Announces Proposed Change of Accounting Auditors [PDF:15KB]
Santen Announces Financial Results for the Year ended March 31, 2003 [PDF:57KB]
Santen to Issue Stock Acquisition Rights for the Purpose of Granting Stock Options [PDF:22KB]
Santen to Shorten Office Term of Directors and Appoint Outside Director [PDF:14KB]
Notice Regarding Share Buyback [PDF:14KB]
Santen Submits New Drug Application to FDA for Levofloxacin 1.5% Ophthalmic Solution [PDF:15KB]
Santen Purchases Own Shares on Market by ToSTNet-2 [PDF:12KB]
Santen to Purchase Own Shares on Market by ToSTNet-2 [PDF:15KB]
Revision of Performance Forecasts[PDF:41KB]
2003-2005 Medium-term Management Plan [PDF:38KB]
Santen Completes Construction Work on North Building of its Nara Research and Development Center [PDF:29KB]
Santen announces its financial results for the six months ended September 30, 2002 [PDF:15KB]
Revision of Performance Forecasts [PDF: 21KB]
Revision of Performance Forecasts [PDF:25KB]
Santen to Launch OTC Eye Drops SANTE 40 [PDF:25KB]
Santen Launches OPHTHAGREEN for Intravenous Injection 25mg, Fluorescein Fundus Angiography Contrast Medium [PDF:20KB]
Changes to Principal Shareholder [PDF:16KB]
The 90th Annual General Meeting of Shareholders was held and four items of business were resolved.
News Archive
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved